Uterine Fibroid (Uf) Treatment Device Market Size to grow by USD 3034.4 million between 2024-2028
According to a research report “ Uterine Fibroid (Uf) Treatment Device Market” by Therapeutic Area (Invasive treatment, Minimally invasive treatment, Non-invasive treatment) Technology (Surgical techniques, Laparoscopic techniques, Ablation techniques, Embolization techniques) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 3034.4 million, at a CAGR of 9.45% during the forecast period. In alignment with the World Bank Group's report, healthcare expenditure in North America, comprising Canada and the US, witnessed a significant growth trajectory, expanding from 15% in 2010 to an estimated percentage by 2020. Simultaneously, developing economies, such as India and China, have experienced substantial economic growth, leading to a surge in healthcare spending. The global healthcare market is projected to grow by 5.8% in 2021, reaching USD8.8 trillion. This trend presents a lucrative business opportunity for healthcare companies, necessitating the development of innovative technologies, delivery models, and business strategies to cater to these emerging markets..
Browse market data tables, figures, and in-depth TOC on “Uterine Fibroid (Uf) Treatment Device Market” by Therapeutic Area (Invasive treatment, Minimally invasive treatment, Non-invasive treatment) Technology (Surgical techniques, Laparoscopic techniques, Ablation techniques, Embolization techniques) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample
By Therapeutic Area, the Invasive treatment segment is projected to dominate the market size in 2024
The invasive segment of the global uterine fibroid (UF) treatment device market is characterized by surgical methods that offer a high degree of assurance for fibroid removal or destruction. This segment dominates the market due to the prevalent preference for surgical interventions among women. Notable procedures within this category include hysterectomy and myomectomy, which are favored by physicians for their proven efficacy, safety, and long-term outcomes.
By Technology, Surgical techniques segment is expected to hold the largest market size for the year 2024
The global uterine fibroid (UF) treatment device market encompasses surgical techniques as a significant segment, which focuses on the surgical removal of fibroids to restore uterine function. These procedures include invasive options such as hysterectomy, myomectomy, hysteroscopic surgery, laparoscopic surgery, and robot-assisted surgery. Patients opt for surgical techniques to alleviate symptoms like heavy menstrual bleeding, pain, and discomfort, or when fibroids cause considerable pressure. Notable products in this segment include Hologic's MyoSure tissue removal system, enabling hysteroscopic fibroid removal in an outpatient setting.
North America is forecasted to hold the largest market size by region in 2024
The Uterine Fibroid (UF) Treatment Device market represents a significant growth opportunity for medical device manufacturers. These devices, which include embolization agents, surgical instruments, and minimally invasive systems, address the needs of the millions of women diagnosed with uterine fibroids annually. Market expansion is driven by increasing awareness, technological advancements, and a growing preference for minimally invasive procedures. Key players in this market include Merck KGaA, Boston Scientific, and Medtronic.
The Uterine Fibroid (Uf) Treatment Device Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:
.
For insights on company offerings- Request a sample report!
Research Analysis Overview
Uterine fibroids (UF), also known as leiomyomas, are benign tumors that commonly affect middle-aged women, particularly those with a familial predisposition, overweight, hypertension, or in the premenopausal state. Severe complications from UF can include frequent urination, infertility, pelvic pain, and excessive menstrual bleeding. Traditional treatments for UF have included hysterectomy, a surgical procedure with significant risks and recovery time. However, contemporary OB/GYN practices are increasingly turning to minimally invasive procedures, such as those utilizing morcellators. Morcellators are technologically sophisticated devices that allow for less invasive removal of fibroids, reducing the risk of complications. A non-surgical alternative is the use of a collagen-degrading enzyme, which can be administered through a catheter, dissolving the fibroid tissue. Despite these advancements, it's essential to note that UF treatment choices depend on various factors, including age, race, and individual risk factors. Some fibroids may not require treatment at all, while others may benefit from dietary modifications or medication. Always consult with a healthcare professional for personalized recommendations.
Market Research Overview
Uterine fibroids, also known as leiomyomas or myomas, are non-cancerous tumors that affect middle-aged women, particularly those in the premenopausal state, overweight, or with a familial predisposition. These benign tumors can cause various symptoms such as reproductive dysfunction, increased urinary frequency, bloating, anemia, and pelvic pain. Traditional treatments for uterine fibroids include invasive procedures like myomectomy and hysterectomy, which can result in severe complications and prolonged recovery time. Contemporary OB/GYN is focusing on less invasive procedures such as myolysis, which uses a collagen-degrading enzyme to destroy fibroid tissue. Telemedicine platforms and home healthcare services are also offering non-surgical alternatives like Raloxifene, Mefenamic acid, Levonorgestrel, Progesterone, Triptorelin, Goserelin, and Leuprolide. Ablation techniques like radiofrequency ablation (RFA) and embolization techniques are minimally invasive and have fewer side effects than open surgeries. Minimally invasive procedures like laparoscopic techniques using morcellators have gained popularity due to their speedy recovery and smaller incisions. However, there are risks associated with these procedures, including the spread of fibroid tissue. The Fibroids Project and White Dress Project aim to raise awareness during Fibroids Awareness Month. Symptoms of uterine fibroids include frequent urination, infertility, and excessive menstrual bleeding. Risk factors include age, race, hypertension, and diet. Severe complications can include heavy bleeding, anemia, and pressure on the bladder or rectum. It is essential to consult a healthcare professional for proper diagnosis and treatment options.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
